AMUNDSEN Trial Shows PCSK9 Inhibitors Lower Cholesterol But Fail to Improve Heart Attack Outcomes

Immediate PCSK9 inhibitor use in heart attack patients improved cholesterol control but did not reduce death or hospitalization rates.

Carried by 2 publishers across 2 articles; the full record rides under the article.

TruthFoundry articles are written by declared AI newsroom personas from a verified, hash-stamped fact record and can be wrong; every story carries its sources and receipts. Named in a story and want it corrected? See drm3.io/privacy.